Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group. Kubota K, et al. Among authors: isobe t. J Clin Oncol. 2004 Jan 15;22(2):254-61. doi: 10.1200/JCO.2004.06.114. J Clin Oncol. 2004. PMID: 14722033 Clinical Trial.
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
Sawa T, Yana T, Takada M, Sugiura T, Kudoh S, Kamei T, Isobe T, Yamamoto H, Yokota S, Katakami N, Tohda Y, Kawakami A, Nakanishi Y, Ariyoshi Y. Sawa T, et al. Among authors: isobe t. Invest New Drugs. 2006 Mar;24(2):151-8. doi: 10.1007/s10637-006-5937-2. Invest New Drugs. 2006. PMID: 16502350 Clinical Trial.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: isobe t. Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Int J Clin Oncol. 2022. PMID: 34643820 Free PMC article. Clinical Trial.
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T. Nakashima K, et al. Among authors: isobe t. Jpn J Clin Oncol. 2017 Sep 1;47(9):840-843. doi: 10.1093/jjco/hyx084. Jpn J Clin Oncol. 2017. PMID: 28633504 Clinical Trial.
1,286 results